// App-Quantinova.ai

4705 : Therapeutic activity of bivalent BRD4 inhibitor AZD5153 in hematological cancers

Researchers

Presenter

  • Huawei (Ray) Chen

Principal Investigators

  • Garrett Rhyasen

  • Austin Dulak

  • Wendy Wang

  • Phil Petteruti

  • Ian Dale

  • Tony Cheung

  • Shenghua Wen

  • Lilian Castriotta

  • Deborah Lawson

  • Mike Collins

  • Miika Ahdesmaki

  • Graeme Walker

  • Al Rabow

  • Jonathan Dry

  • Corinne Reimer

  • Paul Lyne

  • Steve Fawell

  • MIke Waring

  • Mike Zinda

  • Ed Clark

Medical Centers

  • Astrazeneca R and D Boston, Waltham, MA

  • Astra Zeneca, Cambridge, United Kingdom

  • AstraZeneca, Alderley Park, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Hematological malignancies

  • Acute myelocytic leukemia

  • Multiple Myeloma

  • B cell lymphomas

  • Lymphomas

  • Solid malignancies

Biomarkers

  • cMYC

  • Hexamethylene Bisacetamide Inducible 1

Drug/Treatment

  • AZD5153

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved